ID   K#1 50K
AC   CVCL_1H11
SY   K#1 50k; K #1 50K; CD8+ K#1 50K
DR   Wikidata; Q54899230
RX   Patent=US6358511;
RX   PubMed=11752148;
RX   PubMed=16940531;
CC   Characteristics: Has potent HIV-1-inhibitory activity.
CC   Doubling time: 2 days (Patent=US6358511).
CC   Transformant: NCBI_TaxID; 10381; Saimiriine herpesvirus 2 (Herpesvirus saimiri).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Adult
CA   Transformed cell line
DT   Created: 08-07-15; Last updated: 29-06-23; Version: 7
//
RX   Patent=US6358511;
RA   Klotman M.E., Mosoian A., Teixeira A.;
RT   "Inhibitors of HIV infection.";
RL   Patent number US6358511, 19-Mar-2002.
//
RX   PubMed=11752148; DOI=10.1128/JVI.76.2.569-581.2002; PMCID=PMC136805;
RA   Chang T.L.-Y., Mosoian A., Pine R., Klotman M.E., Moore J.P.;
RT   "A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human
RT   immunodeficiency virus type 1 replication through STAT1 activation.";
RL   J. Virol. 76:569-581(2002).
//
RX   PubMed=16940531; DOI=10.1128/JVI.00589-06; PMCID=PMC1563913;
RA   Mosoian A., Teixeira A., High A.A., Christian R.E., Hunt D.F.,
RA   Shabanowitz J., Liu X.-Y., Klotman M.E.;
RT   "Novel function of prothymosin alpha as a potent inhibitor of human
RT   immunodeficiency virus type 1 gene expression in primary
RT   macrophages.";
RL   J. Virol. 80:9200-9206(2006).
//